{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:56Z","timestamp":1747181096147,"version":"3.40.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,13]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Polycystic ovary syndrome (PCOS) is a frequent endocrine disorder in women, it is the principal cause of infertility and amenorrhea. Due to its high recurrence rate, poor prognosis and serious complications, more works on the research of PCOS are needed. Therefore, we performed a protocol for systematic review and meta-analysis to investigate the efficacy and safety of glucagon-like peptide-1 receptor agonists on ovarian dysfunction in PCOS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study protocol has been registered in the PROSPERO and the registration number is CRD42020188247. The procedure of this protocol will be conducted according to the Preferred Reporting Item for Systematic Review and Meta-analysis Protocols guidance. A comprehensive search of several databases from 1966 to November 2022 will be conducted. The databases includes Ovid Medline In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and PubMed. The risk of bias of the included studies will be assessed using the Cochrane tool of risk of bias. All statistical analyses will be conducted using the software program Review Manager version 5.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results of this systematic review will be published in a peer-reviewed journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This systematic review will provide evidence to judge whether glucagon-like peptide-1 receptor agonist is superior to metformin in patients with PCOS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032312","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:56:53Z","timestamp":1673657813000},"page":"e32312","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effects of GLP-1 on ovarian dysfunction in polycystic ovary syndrome: A protocol for systematic review and meta-analysis"],"prefix":"10.1097","volume":"102","author":[{"given":"Caifeng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gynaecology, Lanzhou Maternal and Child Health Hospital, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongling","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Lanzhou Maternal and Child Health Hospital, Gansu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Lanzhou Maternal and Child Health Hospital, Gansu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2973-4182","authenticated-orcid":false,"given":"Dianchen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Lanzhou Maternal and Child Health Hospital, Gansu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R2-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020583","article-title":"Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing.","volume":"23","author":"Sadeghi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.medcli.2018.11.019","article-title":"Polycystic ovary syndrome in adult women.","volume":"152","author":"Ortiz-Flores","year":"2019","journal-title":"Med Clin"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/ijamh-2021-0073","article-title":"Polycystic ovary syndrome and infertility: an update.","volume":"34","author":"Zehravi","year":"2021","journal-title":"Int J Adolesc Med Health"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","article-title":"Polycystic ovary syndrome.","volume":"10","author":"Joham","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/09513590.2017.1395841","article-title":"Treatment strategies for women with polycystic ovary syndrome.","volume":"34","author":"Jin","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"R7-20250504","first-page":"D7506","article-title":"Lifestyle changes in women with polycystic ovary syndrome.","volume":"3","author":"Lim","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3390\/nu13061848","article-title":"Polycystic ovary syndrome in insulin-resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility.","volume":"13","author":"Calcaterra","year":"2021","journal-title":"Nutrients"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13679-021-00437-x","article-title":"Weight management in adolescents with polycystic ovary syndrome.","volume":"10","author":"Moore","year":"2021","journal-title":"Curr Obes Rep"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jama.2021.23769","article-title":"Diagnosis and treatment of polycystic ovary syndrome.","volume":"327","author":"Huddleston","year":"2022","journal-title":"JAMA"},{"key":"R11-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/nu13030896","article-title":"Relation between inflammation, oxidative stress, and macronutrient intakes in normal and excessive body weight adolescent girls with clinical features of polycystic ovary syndrome.","volume":"13","author":"Mizgier","year":"2021","journal-title":"Nutrients"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists.","volume":"105","author":"Cena","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1).","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.peptides.2017.12.009","article-title":"Newer GLP-1 receptor agonists and obesity-diabetes.","volume":"100","author":"Brown","year":"2018","journal-title":"Peptides"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed.","volume":"58","author":"Deeks","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"R19-20250504","first-page":"376","article-title":"Polycystic ovary syndrome, amenorrhea and the diagnostic role of anti-Mullerian hormone.","volume":"45","author":"Capuzzo","year":"2020","journal-title":"Minerva Endocrinol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:39:02Z","timestamp":1746326342000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032312","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}